Introduction To HIV 1 & 2 Antibody Test
HIV is the virus that causes AIDS (acquired immunodeficiency syndrome). AIDS is the final, most serious stage of an HIV infection. The HIV 1 & 2 antibody test is a diagnostic test used to detect the presence of antibodies against HIV types 1 and 2 in the blood. These antibodies are produced by the immune system in response to HIV infection.
Differentiating HIV Types 1 & 2
HIV is of two types: HIV-1 and HIV-2. While HIV-1 is more common globally, HIV-2 is primarily found in West Africa. The HIV 1&2 antibody test is designed to detect antibodies for both types, ensuring a comprehensive screening.
HIV Test Price in Digboi - Compare Prices at 1 Labs
Name
Proc. Time
Rating
Price
What Is An HIV Antibody Test?
HIV antibody tests are pivotal in detecting HIV infection, as they seek out specific disease-fighting proteins called HIV antibodies in bodily fluids like blood, saliva, or urine. These antibodies are produced by the immune system as a response to HIV infection. Interestingly, individuals may produce antibodies at different rates, meaning that detection timeframes can vary. Some may produce detectable antibodies as early as 23 days after infection, while for others, it might take up to 90 days for enough antibodies to show up on the test. No fasting is required before getting this test done. Book an HIV 1 & 2 Antibody test in {#var#} at affordable price of ₹480*
What Is Detected Through An HIV Test?
Presence of HIV Antibodies : The primary purpose of HIV testing is to detect the presence of antibodies produced by the immune system in response to HIV infection. Most HIV tests, including rapid tests and laboratory-based assays, detect antibodies specific to HIV types 1 and 2. The presence of these antibodies indicates exposure to HIV..
HIV Antigen: In addition to antibodies, some HIV tests also detect HIV antigens. Antigens are viral proteins produced by the HIV virus itself. The presence of HIV antigens suggests active HIV replication in the body and may indicate acute or recent HIV infection.
HIV RNA/Viral Load: Molecular tests, such as nucleic acid amplification tests (NAATs) or viral load tests, directly detect the genetic material (RNA) of the HIV virus. These tests measure the amount of HIV RNA in the blood and provide quantitative information about viral replication levels. HIV RNA testing is particularly useful for diagnosing acute HIV infection and monitoring treatment effectiveness.
Early & Established Infection: HIV tests are capable of detecting HIV infection at various stages, including acute, early, and established infection. Acute HIV infection refers to the period immediately after HIV exposure when the virus is rapidly replicating in the body. Early detection during this phase is crucial for timely intervention and prevention of further transmission. Established infection refers to chronic HIV infection, characterised by stable viral replication and the presence of HIV antibodies.
Differentiating HIV Types: HIV tests can distinguish between HIV types 1 and 2, the two main strains of the virus. While HIV-1 is more prevalent globally, HIV-2 is primarily found in West Africa. Differentiating between HIV types is important for accurate diagnosis and appropriate management of HIV infection.
Screening For Coinfections & Comorbidities: HIV testing often includes screening for coinfections and comorbidities associated with HIV/AIDS. This may include testing for sexually transmitted infections (STIs), viral hepatitis (such as hepatitis B and hepatitis C), tuberculosis (TB), and other opportunistic infections. Detecting and treating these conditions is essential for comprehensive HIV care.
Who Needs To Take HIV 1 & 2 Antibody Test?
HIV 1&2 antibody testing is recommended for a diverse range of individuals, reflecting the complex landscape of HIV transmission and risk factors. Those who are sexually active, especially with multiple partners or without consistent condom use, should prioritise testing as part of routine sexual health care. Individuals who inject drugs face heightened risks due to shared needles and syringes, necessitating regular testing to prevent HIV transmission within this community. Men who have sex with men (MSM) are disproportionately affected by HIV/AIDS and should undergo routine testing to ensure early detection and access to appropriate care. Pregnant individuals require testing to prevent mother-to-child transmission during pregnancy, childbirth, and breastfeeding. Partners of HIV-positive individuals or those with unknown status benefit from testing to safeguard their own health. Book an HIV 1 & 2 Antibody test in Digboi at affordable price of ₹140*. Additionally, individuals with a history of sexually transmitted infections, healthcare workers, and those from high-prevalence populations should seek testing to address specific risk factors. Preconception counselling and concerns about recent exposure also warrant prompt testing to facilitate informed decision-making and access to support services. Through targeted testing initiatives, we can empower individuals to take control of their health, reduce transmission rates, and improve overall outcomes in the fight against HIV/AIDS.
Methods Of Conducting HIV 1 & 2 Antibody Tests
Antibody tests for HIV can be conducted using various methods, offering flexibility and accessibility to individuals seeking testing. Here are the different ways HIV antibody tests can be performed:
What Is The Window Period For An HIV Test?
It’s important to note that there is a window period between HIV infection and the production of detectable antibodies. During this time, the test may not accurately detect the virus. For most people, antibodies can be detected within3 to 12 weeks after infection. However, insome cases, it may take longer.
Why HIV 1 & 2 Antibody Test Matters?
Knowing one’s HIV status empowers individuals to take proactive steps to protect themselves and prevent transmission to others. By undergoing regular HIV testing, individuals can play an active role in controlling the spread of HIV/AIDS within communities. Furthermore, the availability of accurate and reliable antibody testing contributes to efforts aimed at reducing stigma surrounding HIV, promoting education, and encouraging open discussions about sexual health and HIV prevention. Ultimately, the HIV 1 & 2 antibody test matters because it is a cornerstone of HIV/AIDS prevention, treatment, and care, serving as a crucial tool in the global fight against the epidemic. Book anHIV 1 & 2 Antibody test in {#var#} at affordable price of ₹480*
What Do The Results Mean?
Negative Result:
A negative result means that no HIV antibodies were detected in the blood sample. It suggests that the individual tested does not have HIV infection at the time of testing.
However, it’s important to note that a negative result does not necessarily mean the individual is HIV-negative, especially if they were recently exposed to HIV. It can take time for the body to produce enough antibodies to be detected by the test, a period known as the “window period”.
Individuals at ongoing risk of HIV exposure should consider repeat testing after the window period to confirm their HIV status.
Positive Result:
A positive result means that HIV antibodies were detected in the blood sample. It suggests that the individual tested is likely to have HIV infection.
A positive result on an HIV 1&2 antibody test requires further confirmatory testing to confirm the diagnosis of HIV infection. This may involve additional antibody tests, HIV viral load testing, or HIV nucleic acid testing (NAT).
A confirmed positive result indicates that the individual is living with HIV and requires access to medical care, treatment, and support services. Early diagnosis and initiation of antiretroviral therapy (ART) can improve health outcomes and reduce the risk of HIV transmission to others.
| Laboratory Test | Timepoint or Frequency of Testing | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Entry Into Care | ART Initiationb or Modification | 4 to 8 Weeks After ART Initiation or Modification | Every 3 Months | Every 6 Months | Every 12 Months | Treatment Failure | Clinically Indicated | If ART Initiation Is Delayedc | |
| HIV Antigen/Antibody Test | √ If HIV diagnosis has not been confirmed | ||||||||
| CD4 Count | √ | √ | √d If CD4 count is <300 cells/mm3 | √ During the first 2 years of ART, if CD4 count is ≥ 300 cells/mm3 | After 2 Years on ART with Consistently Suppressed Viral Load CD4 Count 300–500 cells/mm3:
CD4 Count >500 cells/mm3:
| √ | √ | Every 3–6 months | |
| HIV Viral Load | √ | √ | √e | √f | √f | √ | √ | Repeat testing is optional | |
| Genotypic Resistance Testing (PR/RT Genes)g | √ | √ | √ | √ | √ | ||||
| Genotypic Resistance Testing (Integrase Genes)g | √ If transmitted INSTI resistance is suspected or if there is a history of CAB-LA use for PrEP | √f If transmitted INSTI resistance is suspected or if there is a history of INSTI use | √ If there is a history of INSTI use | √ If there is a history of INSTI use | |||||
| Tropism Testing | √ If considering a CCR5 antagonist | √ If considering a CCR5 antagonist, or for patients with virologic failure on a CCR5 antagonist | √ | ||||||
| HLA-B*5701 Testing | √ If considering ABC | ||||||||
| Hepatitis B Serology (HBsAb, HBsAg, HBcAb total)h,i,j | √ | In patients not immune to HBV, consider retesting if switching to a regimen that does not contain TDF or TAF | √ Including before starting HCV DAA | ||||||
| Hepatitis C Screening (HCV antibody or, if indicated, HCV RNA)k | √ | √ Repeat HCV screening for at-risk patientsl | √ | ||||||
| Basic Metabolic Panelm,n | √ | √ | √ | √ | √ | √ Every 6–12 months | |||
| ALT, AST, Total Bilirubin | √ | √ | √ | √ | √ | √ Every 6–12 months | |||
| CBC with Differentialo | √ | √ | √ When monitoring CD4 count, if required by lab | √ When monitoring CD4 count, if required by lab | √ When no longer monitoring CD4 count | √ | |||
| Lipid Profilep | √ | Consider 1–3 months after ARV initiation or modification | √ If normal at baseline but with CV risk | If normal at baseline, every 5 years or if clinically indicated | |||||
| Random or Fasting Glucoseq | √ | √ | √ | √ | |||||
| Urinalysisn,r | √ | √ e.g., in patients with CKD or DM | |||||||
| Pregnancy Tests | √ | √ | √ | ||||||
Risks Involved With HIV 1 & 2 Antibody Test
The HIV 1&2 antibody test is generally considered safe, with minimal risks associated with the procedure itself. The test typically involves collecting a blood sample through a venipuncture (blood draw) from a vein in the arm or, in some cases, using a finger prick for rapid tests. While the blood draw may cause minor discomfort or bruising at the puncture site, these effects are usually temporary and mild. Additionally, individuals may experience mild anxiety or emotional distress related to undergoing HIV testing and awaiting the test results. However, healthcare providers are trained to offer support and counselling to address any concerns or apprehensions during the testing process. Overall, the benefits of HIV testing in terms of early detection, access to treatment, and prevention of HIV transmission far outweigh the minimal risks associated with the test itself. It’s important for individuals to prioritise their sexual health and undergo regular HIV testing as part of routine healthcare maintenance, especially if they are at increased risk of HIV exposure.
Other Important Lab Tests
Additional lab tests are available to assist your healthcare provider in obtaining crucial health-related data and selecting appropriate HIV medications.
Blood Chemistry Tests: This set of tests analyses various chemicals present in your blood, aiding in the assessment of organ health, particularly focusing on the heart, liver, and kidneys. Healthcare professionals utilise these tests to detect potential complications arising from HIV infection and to identify side effects resulting from HIV medications.
CD4 Percentage: This measures how many white blood cells are actually CD4 cells. CD4 cell counts are typically used to assess a person’s immune function. A CD4 percentage can also be used which is less likely to vary between blood tests unlike CD4 counts, which can vary from month to month or day to day.
Complete Blood Count (CBC): This test measures the concentration of red blood cells, white blood cells, and platelets in a blood sample. It helps keep track of overall health and spot infections/medical issues.
Drug Resistance Tests: HIV has the capability to mutate, rendering certain HIV medications ineffective. A drug resistance test assists healthcare providers in determining which HIV medications may not be efficacious against the strain of HIV, aiding in the selection of the most suitable treatment options.
Fasting Glucose (Blood Sugar) Test: This test evaluates your blood glucose levels. Certain HIV medications have the potential to impact blood sugar levels, which could result in complications such as diabetes. Undergoing a glucose test at the commencement of HIV treatment is crucial to inform the selection of appropriate HIV medications. Repeat tests are necessary to monitor potential rises in blood glucose levels.
Fasting Lipid Panel (Cholesterol and Triglycerides): Lipids are fats or fat-like compounds present in the blood and bodily tissues. A lipid panel helps determine your lipid, cholesterol and triglyceride levels. This is significant as certain HIV medications may influence cholesterol levels and the body’s fat processing and storage mechanisms. Elevated lipid levels can increase susceptibility to various medical issues, notably heart problems. Understanding lipid levels at the onset of treatment is crucial for informing medication selection and managing high lipid levels to mitigate potential health complications.
Hepatitis A, B, and C Tests: Individuals living with HIV may also be affected by viral hepatitis. These blood tests ascertain whether there is current or previous infection with Hepatitis A, B, or C. Screening for hepatitis A, B, and C infection assists healthcare providers in assessing the need for treatment or determining eligibility for hepatitis A or B vaccination.
PAP Test (Cervical and Anal): A cervical Pap test, also known as a Pap smear, is conducted to detect cancers and precancers in the cervix, the lower part of the uterus that connects to the vagina. This test entails collecting cell samples directly from the cervix using a swab. Similarly, an anal Pap test can be performed on individuals of any gender, involving the collection of cell samples from the anal canal with a swab. Among women living with HIV, abnormal cell growth in the cervix is common, while both men and women with HIV may have abnormal anal cells. If left untreated, these may develop into cancer.
Pregnancy Test: This examination indicates whether a woman is pregnant. If you are HIV-positive and pregnant, taking antiretroviral therapy (ART) during pregnancy, labour, and delivery can significantly reduce the risk of transmitting HIV to your baby and safeguard your own health.
Sexually Transmitted Disease (STD) Screening: These screening assessments examine for syphilis, gonorrhea, and chlamydia. Untreated STDs can result in severe health complications and may also elevate the risk of transmitting HIV to others.
How To Prevent HIV
Condom Use: Consistent and correct use of condoms during sexual activity, including vaginal, anal, and oral sex, can significantly reduce the risk of HIV transmission. Condoms act as a barrier to prevent the exchange of bodily fluids that may contain HIV.
PrEP (Pre-Exposure Prophylaxis): PrEP involves taking a daily oral medication (usually a combination of tenofovir and emtricitabine) by HIV-negative individuals who are at high risk of HIV exposure. PrEP has been shown to be highly effective in preventing HIV transmission when taken as prescribed.
Treatment as Prevention: Treatment with antiretroviral therapy (ART) not only improves the health of people living with HIV but also significantly reduces the risk of HIV transmission to sexual partners. Virally suppressed individuals with HIV have effectively no risk of transmitting the virus sexually.
Needle and Syringe Programs: Providing access to sterile needles and syringes through needle exchange programs or pharmacies can reduce the risk of HIV transmission among people who inject drugs. These programs also offer education, counselling, and referrals to support services.
HIV Testing and Counselling: Regular HIV testing and counselling can help individuals know their HIV status, access appropriate prevention services, and make informed decisions about their sexual health. Early diagnosis of HIV allows for timely access to treatment and care, which can improve health outcomes and reduce transmission.
Education and Awareness: Providing accurate information about HIV transmission, prevention methods, and risk reduction strategies through educational campaigns, community outreach, and school-based programs can empower individuals to make healthier choices and reduce their risk of HIV infection.
Sexual Health Services: Access to comprehensive sexual health services, including STI screening, contraception, and reproductive health care, is essential for promoting overall sexual health and reducing the risk of HIV transmission.
Gender Equality and Empowerment: Addressing underlying social and structural factors, such as gender inequality, poverty, stigma, and discrimination, is crucial for creating environments that support HIV prevention efforts and promote the rights and well-being of all individuals.